Trial Profile
Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lanthanum carbonate (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Bayer
- 27 Nov 2015 New trial record